1. Phyllis A. Balch. Stress. In: a member of Penguin Group (USA) Inc. Prescription for Nutritional Healing. Forth Edition. New York: AVERY; 2006. p. 57-58.
283. Zammit VA et al. Carnitine, mitochondrial function and therapy. Adv Drug Deliv Rev. 2009 Nov 30;61(14):1353-62.
284. Mynatt RL. Carnitine and type 2 diabetes. Diabetes Metab Res Rev. 2009 Sep;25 Suppl 1:S45-9.
285. Hota KB et al. Acetyl-L-carnitine-mediated neuroprotection during hypoxia is attributed to ERK1/2-Nrf2-regulated mitochondrial biosynthesis. Hippocampus. 2011 May 3. doi: 10.1002/hipo.20934.
286. Ando S et al. Enhancement of learning capacity and cholinergic synaptic function by carnitine in aging rats. J Neurosci Res. 2001 Oct 15;66(2):266-71.
287. Barhwal K et al. Hypoxia-induced deactivation of NGF-mediated ERK1/2 signaling in hippocampal cells: neuroprotection by acetyl-L-carnitine. J Neurosci Res. 2008 Sep;86(12):2705-21.
288. Alves E et al. Acetyl-L-carnitine provides effective in vivo neuroprotection over 3,4-methylenedioximethamphetamine-induced mitochondrial neurotoxicity in the adolescent rat brain. Neuroscience. 2009 Jan 23;158(2):514-23.
289. Taglialatela G et al. Acetyl-L-carnitine enhances the response of PC12 cells to nerve growth factor. Brain Res Dev Brain Res. 1991 Apr 24;59(2):221-30.
290. Taglialatela G et al. Neurite outgrowth in PC12 cells stimulated by acetyl-L-carnitine arginine amide. Neurochem Res. 1995 Jan;20(1):1-9.
291. Montgomery SA et al. Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimers disease. Int Clin Psychopharmacol. 2003 Mar;18(2):61-71.
